Tuesday, April 09, 2024 10:47:08 AM
<<<<<<< Hope he doesn't wait for the SofPulse trial to finish and publish them together. >>>>>>>
ENDV, the current owner of SofPulse, purchased the SofPulse patents, already FDA Cleared, 6 years ago for $4.5 million . Neither of their own research projects, Immunotronics and Cytotronics, have ever been FDA Cleared.
With a current Market Cap of $1.065 million the ENDV CEO is trying to spin off SofPulse into its own company. They are looking for an analyst that will value the new company at $50-100 million.
ENDV has been trying to purchase a concrete company for several years. That is correct, a medical device company was trying to buy a concrete company. Big surprise, that 'deal' fell through.
ENDV's SP is currently at .0032, this after a 1 for 1,000 Reverse Split 4 years ago. If you had one million shares of ENDV before the RS you now have one thousand shares. To compare ENDV to BIEL, which has no RS, you can add 3 zeros (to the right of the decimal point) back into their current SP, which equals .0000032 .
To the 'Usual Suspects' that claim BIEL is a scam, Allan Collier CEO of ENDV would say, Hold my beer and I will show you what a real scam looks like.
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM